Table 1 Demographic and clinical characteristics of phase 3 empyema study cohort.
Variable | All patients (n = 204) | Survivorsa (n = 158) | Non-survivorsa (n = 46) | p value |
|---|---|---|---|---|
Age (years) | 66.46 ± 15.10 | 64.81 ± 15.41 | 72.13 ± 12.58 | 0.004 |
Gender | ||||
Male | 163(79.9%) | 125(79.1%) | 38(82.6%) | 0.753 |
Female | 41(20.1%) | 33(20.9%) | 8(17.4%) | 0.516 |
Affected side | ||||
Right | 106(52.0%) | 78(49.4%) | 28(60.9%) | 0.253 |
Left | 96(47.0%) | 79(50.0%) | 17(37.0%) | 0.163 |
Bilateral | 2(1.0%) | 1(0.6%) | 1(2.2%) | 0.564 |
Comorbidity | ||||
Hypertension | 132(64.7%) | 100(63.3%) | 32(69.6%) | 0.544 |
Diabetes | 92(44.9%) | 72(45.6%) | 20(43.5%) | 0.833 |
Cardiovascular disease | 69(33.8%) | 46(29.1%) | 23(50.0%) | 0.018 |
COPD | 46(22.5%) | 33(20.9%) | 13(28.3%) | 0.317 |
End-stage renal disease | 30(14.7%) | 16(10.1%) | 14(30.4%) | 0.002 |
Lab data | ||||
White blood cell (103/µl) | 14.27 ± 7.03 | 14.08 ± 6.68 | 14.92 ± 8.14 | 0.478 |
Hemoglobin (g/dL) | 9.88 ± 1.97 | 10.02 ± 2.04 | 9.42 ± 1.64 | 0.068 |
Pleural effusion data | ||||
Pleural pH ≦ 7.2 | 90(53.6%) | 75(58.1%) | 15(38.5%) | 0.054 |
Pleural glucose ≦ 40 mg/dL | 92(53.2%) | 67(51.5%) | 25(58.1%) | 0.567 |
Pleural LDH ≧ 1000 IU/L | 126(61.5%) | 96(73.8%) | 30(71.4%) | 0.803 |
MTBC | 10(4.9%) | 6(3.8%) | 4(8.7%) | 0.248 |
Duration to surgery (days) | 13.36 ± 42.79 | 6.12 ± 10.65 | 38.24 ± 83.95 | 0.013 |
Operative time (minutes) | 117.22 ± 40.66 | 118.94 ± 40.65 | 111.28 ± 40.56 | 0.262 |
Length of ICU admission (days) | 12.83 ± 37.26 | 6.29 ± 9.83 | 35.28 ± 72.53 | 0.010 |
Length of hospital stay (days) | 51.80 ± 158.91 | 24.94 ± 21.09 | 144.09 ± 318.01 | 0.015 |
